BeOne Medicines (NASDAQ:ONC) Insider Sells 132 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 132 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total transaction of $46,973.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Performance

Shares of NASDAQ ONC traded up $0.90 during midday trading on Thursday, reaching $362.68. The company had a trading volume of 123,616 shares, compared to its average volume of 293,283. The business’s 50-day simple moving average is $330.63 and its 200 day simple moving average is $311.25. The stock has a market cap of $39.82 billion, a P/E ratio of 63.85 and a beta of 0.51. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. On average, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Barclays raised their price objective on BeOne Medicines from $403.00 to $407.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating and issued a $370.00 price objective on shares of BeOne Medicines in a research note on Monday, August 10th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Finally, Citigroup restated an “outperform” rating on shares of BeOne Medicines in a research report on Thursday, August 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, BeOne Medicines presently has a consensus rating of “Buy” and an average target price of $402.14.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ONC. EFG International AG purchased a new stake in BeOne Medicines in the 4th quarter worth approximately $25,000. Leonteq Securities AG acquired a new position in shares of BeOne Medicines in the 4th quarter valued at $35,000. Daiwa Securities Group Inc. purchased a new stake in BeOne Medicines during the second quarter worth $35,000. CWM LLC boosted its holdings in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after buying an additional 39 shares in the last quarter. Finally, Group One Trading LLC acquired a new stake in BeOne Medicines during the fourth quarter valued at $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.